BioCryst Pharmaceuticals BCRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$721.81M-2,255,763% | $245.85M+1,018% | $12.9M+192% | $5.09M+140% | $32K+100% | ||
| $461K+39.3% | $394K+27.5% | $335K+7.7% | $329K+2.8% | $331K+8.2% | ||
| $16.03M-25.0% | $23.79M+11.5% | $18.6M+7.8% | $21.3M+61.7% | $21.37M+56.5% | ||
| $4.85M+457% | $515K-76.2% | $1.69M+11.3% | -$1.44M— | $870K-28.7% | ||
| -$60.4M-85.3% | $35.36M+73.3% | $24.58M— | $30.46M— | -$32.59M+26.9% | ||
| -$3.53M-2,776% | $1.94M+437% | $5.92M— | -$160K+90.8% | $132K+112% | ||
| -$749K— | —— | —— | —— | $0— | ||
| $600K— | —— | —— | —— | $0— | ||
| $474K-96.6% | $15.49M+112% | $17K-99.5% | $7.31M-11.4% | $13.99M+264% | ||
| -$61.79M-125% | $291.96M+5,701% | $41.62M— | $41.3M+3,119% | -$27.52M+48.7% | ||
| $403K+182% | $802K+18.8% | $1.34M+2,178% | $179K+15.5% | $143K-39.1% | ||
| $489.48M— | —— | —— | —— | $0— | ||
| $0-100% | $125.5M+218% | $58.63M+118% | $29.34M-73.9% | $48.76M-44.6% | ||
| $221.24M+191% | $49M-15.5% | $73M+106% | $58.65M-46.7% | $76M-35.0% | ||
| —— | -$1.55M— | -$1.55M— | -$1.55M— | -$1.55M— | ||
| -$268.65M-1,092% | -$83.49M-569% | $13.57M+59.9% | $29.13M— | $27.1M-5.8% | ||
| $400M— | —— | —— | —— | $0— | ||
| $19.48M+715% | $657K— | $2.65M+27.0% | $3.42M+1,196% | $2.39M+42.2% | ||
| $345K-33.1% | $424K+19.1% | $513K-7.7% | $536K+33.3% | $516K+32.3% | ||
| $1.19M-12.1% | $6M+94.6% | $628K+141% | $866K-52.9% | $1.35M-42.5% | ||
| $4.95M— | —— | —— | —— | $0— | ||
| $412.55M+77,887% | -$217.96M-5,321% | -$58.81M— | -$73.69M-3,648% | $529K+150% | ||
| -$72K-116% | —— | —— | $1.36M+1,050% | $451K+233% | ||
| $82.04M+14,603% | -$9.56M— | -$4.09M— | -$1.9M+68.0% | $558K+102% | ||
| $6.08M-33.5% | $946K-90.7% | $6.11M-40.1% | $7.53M+48.9% | $9.15M+83.5% | ||
| $1.43M+143,000% | —— | $992K+176% | $1.23M+80.7% | $1K-99.5% | ||
| $697.76M— | —— | —— | —— | $0— | ||
| $149K-72.6% | —— | —— | —— | $544K— | ||
| $600K— | —— | —— | —— | $0— | ||
| $251K+118% | -$1.09M+60.5% | -$707K+65.3% | -$1.15M+67.1% | -$1.38M+56.5% | ||
| $461K+39.3% | —— | —— | —— | $331K— | ||
| —— | $4.39M— | $4.39M— | $4.39M— | $4.39M— | ||
| -$2.81M— | —— | —— | —— | $0— | ||
| —— | $891.5K— | $891.5K— | $891.5K— | $891.5K— | ||
| -$3.53M-2,776% | $1.94M+437% | $5.92M— | -$160K+90.8% | $132K+112% | ||
| -$8.47M+41.8% | $13.19M-42.3% | $18.32M-13.7% | $51.47M— | -$14.55M— | ||
| $74K-64.6% | $0— | $30K-97.8% | $817K+81,600% | $209K— | ||
| $13.29M-1.6% | $13.32M-1.3% | $12.92M-7.8% | $13.4M— | $13.51M— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | -$1.55M— | -$1.55M— | -$1.55M— | -$1.55M— | ||
| $221.24M+191% | $49M-15.5% | $73M+106% | $58.65M-46.7% | $76M-35.0% | ||
| $345K-33.1% | $424K+19.1% | $513K-7.7% | $536K+33.3% | $516K+32.3% | ||
| —— | $3.88M— | $3.88M— | $3.88M— | $3.88M— | ||
| $4.95M— | —— | —— | —— | $0— | ||
| $19.48M+715% | $657K— | $2.65M+27.0% | $3.42M+1,196% | $2.39M+42.2% | ||
| $33K+450% | —— | —— | —— | $6K— | ||
| $476K— | $6.48M— | $12.45M— | $3.96M— | $0— | ||
| $251.66M— | —— | —— | —— | $0— | ||
| $1.43M+143,000% | —— | —— | —— | $1K-99.8% | ||
| $3.17M+1,049% | —— | —— | $67K— | $276K-85.0% | ||
| -$62.19M-125% | $291.16M+5,045% | $40.28M— | $41.12M+2,800% | -$27.66M+48.7% | ||
| -$62.19M-125% | $291.16M+5,045% | $40.28M— | $41.12M+2,800% | -$27.66M+48.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioCryst Pharmaceuticals generate?
- BioCryst Pharmaceuticals (BCRX) generated $313.1M in operating cash flow over the trailing twelve months.
- What is BioCryst Pharmaceuticals's free cash flow?
- After $2.7M of capital expenditures, BioCryst Pharmaceuticals's free cash flow was $310.4M over the trailing twelve months, up 448.8% year over year.
- Where does BioCryst Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
